BioNano Genomics Inc vs Global E Online Ltd — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Global E Online Ltd trades at $39.19 (market cap $6.51B). The key difference: Global E Online Ltd is far larger — about 493.2× BioNano Genomics Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | GLBE | |
|---|---|---|
Market Cap | $13.20M | $6.51B |
Sector | Health | Technology |
52-Week High | $4.92 | $41.59 |
52-Week Low | $1.09 | $27.54 |
Enterprise Value | $15.81M | $5.98B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
GLBE trades at $38.68, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with revenue growth of 33% year-over-year and raised full-year guidance, achieving a 'Rule of 50' metric. Recent acquisition of Passport enhances logistics capabilities, supporting future growth. Valuation remains elevated with a P/E of 57.84 and P/S of 6.7, reflecting high growth expectations.
Outlook is positive driven by robust merchant demand and cross-border expansion, though risks include execution of acquisitions and competitive pressures. Analysts are unanimously bullish with a $38 consensus target, near the current price. Stock investors should monitor earnings consistency and integration success for sustained upside.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →